Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
Cells · 13.09.2023 · 12 (18) · 2266
DOI: 10.3390/cells12182266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 13.09.2023. Verfasst von Ian M Freed und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The University of Kansas, Lawrence, KS 66047, USA. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an innovative approach that will generate renewed interest in using circulating tumor cells (CTCs) to monitor treatment efficacy, which, in this case, used PDAC patients receiving an exploratory new therapy, poly ADP-ribose polymerase inhibitor (PARPi)—niraparib—as a case study. CTCs were enumerated from whole blood using a microfluidic approach that affinity captures epithelial and mesenchymal CTCs using anti-EpCAM and anti-FAPα monoclonal antibodies, respectively. These antibodies were poised on the surface of two separate microfluidic devices to discretely capture each subpopulation for interrogation. The isolated CTCs were enumerated using immunophenotyping to produce a numerical ratio consisting of the number of mesenchymal to epithelial CTCs (denoted “Φ”), which was used as an indicator of response to therapy, as determined using computed tomography (CT). A decreasing value of Φ during treatment was indicative of tumor response to the PARPi and was observed in 88% of the enrolled patients (n = 31). Changes in Φ during longitudinal testing were a better predictor of treatment response than the current standard CA19-9. We were able to differentiate between responders and non-responders using ΔΦ (p = 0.0093) with higher confidence than CA19-9 (p = 0.033). For CA19-9 non-producers, ΔΦ correctly predicted the outcome in 72% of the PDAC patients. Sequencing of the gDNA extracted from affinity-selected CTC subpopulations provided information that could be used for patient enrollment into the clinical trial based on their tumor mutational status in DNA repair genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The University of Kansas, Lawrence, KS 66047, USA.
- Center of Bio-Modular Multiscale Systems for Precision Medicine (CBM2), The University of Kansas, Lawrence, KS 66047, USA.
- Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Cancer Biology, The University of Kansas Medical Center, Cancer Center, Kansas City, KS 66160, USA.
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
ORCID-Profile: Ian M Freed, Weijing Sun, Joaquina Baranda, Prabhakar Chalise, Andrew K Godwin
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIBIB NIH HHS
- NIH Biotechnology Resource Center of BioModular Multi-scale Systems for Precision Medicine
- NCI IMAT
- Kansas Institute for Precision Medicine COBRE
- Children’s Mercy Hospital
- KUCC consortium, GSK—Clinical trial funding
Zitieren
APA
Freed, I. M., Kasi, A., Fateru, O., Hu, M., Gonzalez, P., Weatherington, N., Pathak, H., Hyter, S., Sun, W., Al-Rajabi, R., Baranda, J., Hupert, M. L., Chalise, P., Godwin, A. K., A Witek, M., & Soper, S. A. (2023). Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients. Cells, 12(18), 2266. https://doi.org/10.3390/cells12182266
Vancouver
Freed IM, Kasi A, Fateru O, Hu M, Gonzalez P, Weatherington N, et al. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients. Cells. 2023;12(18):2266. doi:10.3390/cells12182266
BibTeX
@article{Freed2023,
author = {Freed, Ian M and Kasi, Anup and Fateru, Oluwadamilola and Hu, Mengjia and Gonzalez, Phasin and Weatherington, Nyla and Pathak, Harsh and Hyter, Stephen and Sun, Weijing and Al-Rajabi, Raed and Baranda, Joaquina and Hupert, Mateusz L and Chalise, Prabhakar and Godwin, Andrew K and A Witek, Malgorzata and Soper, Steven A},
title = {Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients},
journal = {Cells},
year = {2023},
volume = {12},
number = {18},
pages = {2266},
doi = {10.3390/cells12182266}
}
EUVIMED